© 2022 MJH Life Sciences and AJMC - Managed Care News, Research, and Expert Insights. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
April 13, 2022
Closing out their discussion on cardiovascular disease in prostate cancer, experts share their hopes for future evolution of the treatment landscape.
April 06, 2022
Shared insight on the value of multidisciplinary care and its current state in cardiovascular disease and prostate cancer.
Maria Lopes, MD, MS, elucidates the potential for quality measures and coverage policies to incorporate cardiovascular disease (CVD) and improve outcomes in prostate cancer.
March 30, 2022
Experts share insight on the need for clinical or real-world evidence to further solidify cardiovascular disease risk as an actionable factor in prostate cancer.
Expert perspectives on factors that inform prostate cancer therapy selection while keeping cardiovascular disease in mind.
March 23, 2022
Continuing their discussion on cost of care in prostate cancer, experts reflect on how cardiovascular disease impacts risk-bearing practices and alternative payment models.
Shared insight on the impact that cardiovascular disease has on cost of care in prostate cancer.
March 16, 2022
Experts consider available professional society guidelines on prostate cancer and cardiovascular disease management.
A brief review of factors that may put patients with prostate cancer at increased risk for developing cardiovascular disease.
March 09, 2022
Focusing on available agents in prostate cancer, experts consider how androgen deprivation therapy impacts risk of cardiovascular disease.